Objective To validate the Canada-Denmark (CANDEN) MRI scoring system for the spine in axial spondyloarthritis with updated lesion definitions. Methods Lesion definitions in the CANDEN system were updated and illustrated by a consensus set of reference images. Sagittal spine MRIs of 40 patients with axial spondyloarthritis obtained at baseline and at week 52 after initiation of treatment with the tumour necrosis factor inhibitor golimumab were evaluated in unknown chronology by seven readers blinded to all other data. Results CANDEN MRI spine inflammation score had very good reliability for status scores (single-measure intraclass correlation coefficient (ICC) of 21 reader pairs median of 0.91 (IQR 0.88–0.92)) and change scores (ICC 0.88 (0.86–0.92)). CANDEN MRI spine fat score had good to very good reliability for status scores (ICC 0.79 (0.75–0.86)) and moderate to good reliability for detecting change (ICC 0.59 (0.46–0.73)). CANDEN MRI spine bone erosion score and CANDEN MRI spine new bone formation score had slight to moderate reliability for status scores (ICC 0.38 (0.32–0.52) and 0.39 (0.27–0.49), respectively). Conclusion The CANDEN MRI spine scoring system allows a comprehensive evaluation of inflammation, fat, bone erosion and new bone formation of the spine in patients with axial spondyloarthritis. It demonstrated very good reliability for detecting change in inflammation, moderate to good reliability for detecting change in fat, and slight to moderate reliability for detecting bone erosions and new bone formation. Studies with longer follow-up or patients with more advanced spinal involvement may be needed to reliably detect change in bone erosion and new bone formation scores. Trial registration number NCT02011386.
Background: People with early axial spondyloarthritis experience a diagnostic delay and a similar disease burden as people with axial spondyloarthritis at a later stage of the disease. In many European countries, patients with early axial spondyloarthritis do not have access to an interdisciplinary rehabilitation team. The objective of this study was to develop a new evidence-based physiotherapist-coordinated interdisciplinary rehabilitation intervention for individuals suspected of axial spondyloarthritis. This development of the rehabilitation intervention is part of the SPINCODE project which focusses on early diagnosis and treatment for people with axial spondyloarthritis. Methods: The development of the intervention encompasses: (i) identifying the evidence base and program theories; (ii) modeling and remodeling the intervention; and (iii) describing the developed intervention. Results: The six-month SPINCODE rehabilitation intervention is a physiotherapist-coordinated, interdisciplinary, outpatient rehabilitation intervention at a specialized rheumatology hospital. The intervention consists of: (i) individual physiotherapist-coordinated consultations with assessment, goal setting, tailored physical activity support, and the defined goals, and coordination across the interdisciplinary team at the hospital and across primary and secondary healthcare levels; (ii) group sessions, encompassing patient education and peer support; and (iii) optional individual support from the interdisciplinary team. Physiotherapists from private care working with the patient enrolled in the SPINCODE study are offered digital support from the hospital-based physiotherapists. Conclusions: The developed physiotherapist-led interdisciplinary SPINCODE rehabilitation intervention is ready for feasibility testing.
Introduction: Spondyloarthritis (SpA) comprises a heterogeneous group of chronic inflammatory diseases. Axial SpA (axSpA) predominantly involves the sacroiliac joints and the spine and typically presents with back pain and stiffness. Modern imaging techniques, especially MRI, allow earlier detection of axSpA compared to conventional radiography, but imaging findings still need cautious interpretation to facilitate a clinical diagnosis. This cohort study of patients with suspected SpA is designed to (1) compare demographic, clinical, laboratory, imaging data and patient-reported outcomes (PROs) of patients diagnosed with or without axSpA (2) to identify prognostic factors for the diagnosis of axSpA and high disease activity (3) to compare performance of different imaging modalities for establishing a diagnosis of axSpA. Methods and analysis: The study is a 2-year prospective observational cohort study of consecutive patients with low back pain ≥3 months and ≤3 years and symptom onset at age 18–45 years, suspected of axSpA. Clinical visits are conducted at baseline, week 6, 12 (telephone consultation), 24, 48, 72 and 96. Demographics, clinical data, laboratory findings and PROs are collected. Radiography (only at baseline), MRI, low-dose computed tomography (ldCT) and dual-energy CT (DECT) are performed at baseline and prior to the last study visit. Clinical, laboratory and imaging data are prior to visits at week 6 and week 96 assessed at a multidisciplinary team (MDT) conference involving a musculoskeletal radiologist and a rheumatologist, where a diagnosis of axSpA or not will be determined. Descriptive statistics are used to summarise clinical, PROs and imaging data. Comparisons between axSpA patients and non-axSpA patients are made cross-sectionally at baseline and week 96. We want to investigate and compare the diagnostic performance, the ability to detect structural and inflammatory lesions and the incremental diagnostic value of ldCT and DECT compared to MRI and radiography. Ethics and dissemination: The ethical committee of the Region of Southern Denmark (S-20230055) has approved the study. The study is registered at clinicaltrials.gov ( NCT06337513 ). Results will be presented at both national and international conferences, as well as published in peer-reviewed journals.